Open Label Study (Phase III) of NS-32 in Patients with Iron Deficiency Anemia Associated with Gastrointestinal Diseases

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080224507

Enrollment

Registered

2019-01-10

Start date

2019-02-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Iron Deficiency Anemia

Interventions

investigational material(s) Generic name etc : NS-32 INN of investigational material : Ferric derisomaltose Therapeutic category code : 322 Mineral preparations Dosage and Administration for Investiga

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients confirmed with gastrointestinal bleeding due to gastrointestinal diseases and diagnosed with IDA

Exclusion criteria

Exclusion criteria: Patients with anemia due to causes other than iron deficiency

Design outcomes

Primary

Measure	Time frame
efficacy Maximum change in hemoglobin concentration	—

Secondary

Measure	Time frame
efficacy The duration in which The change in hemoglobin concentration efficacy Percentage of subjects whose hemoglobin concentration has increased by >=2 g/dL efficacy Percentage of subjects with hemoglobin concentration of >=12.0 g/dL	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026